Novartis Annual Results

Annual results

Annual Results 2016 - Jan 25, 2017

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)

Webcast and presentations

Media

Watch the webcast

Download the presentation (PDF 2.9 MB)

Investors

Watch the webcast

Download the podcast (MP3 100 MB)

Download the presentations:
Q4 and Full Year 2016 Results (PDF 2.7 MB)
Development Update (PDF 2.5 MB)
Research Update (PDF 2.4 MB)

Form 20-F 2016

Documents Novartis strategy in line with requirements of the US Securities and Exchange Commission (SEC)

English (PDF 2.9 MB)

Annual Report 2016

Annual Report 2016

Our Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2016.

Download the full 2016 Annual Report:
High resolution (PDF 6.8 MB)
Low resolution (PDF 4.3 MB)

To request a hard copy, fill out the order form.

Visit the Annual Report 2016 section

View archived presentations and webcasts from past events

2016

Annual Results 2016 - Jan 25, 2017

 

Continuing operations2
Key figures1 FY 2016
(USD m)		 FY 2015
(USD m)		 % change
(USD/cc)
Net sales 48,518 49,414 -2 (cc: 0)
Operating income 8,268 8,977 -8 (cc: -3)
Net income 6,698 7,028 -5 (cc: 1)
EPS (USD) 2.82 2.92 -3 (cc: 2)
Free cash flow 9,455 9,259 2

Core		      
Operating income 12,987 13,790 -6 (cc: -2)
Net income 11,314 12,041 -6 (cc: -3)
EPS (USD) 4.75 5.01 -5 (cc: -2)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2. Refers to continuing operations, defined on page 41 of the Condensed Financial Report.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)

Watch the webcast

Download the podcast (MP3 100 MB)

Download the presentations:
Q4 and Full Year 2016 Results (PDF 2.7 MB)
Development Update (PDF 2.5 MB)
Research Update (PDF 2.4 MB)

2015

Annual Results 2015 - Jan 27, 2016

 

Continuing operations2
Key figures1 FY 2015
(USD m)		 FY 2014
(USD m)		 % change
(USD/cc)
Net sales 49,414 52,180 -5 (cc: 5)
Operating income 8,977 11,089 -19 (cc: -2)
Net income 7,028 10,727 -34 (cc: -18)
EPS (USD) 2.92 4.39 -33 (cc: -17)
Free cash flow 9,259 10,934 -15

Core		      
Operating income 13,790 14,473 -5 (cc: 10)
Net income 12,041 12,653 -5 (cc: 9)
EPS (USD) 5.01 5.19 -3 (cc: 10)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 53 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

2. Refers to continuing operations, defined on page 43 of the Condensed Financial Report.

 

Media release

English (PDF 0.5 MB)

Deutsch (PDF 0.5 MB)

Français (PDF 0.8 MB)

 

Condensed financial report (PDF 0.6 MB)

 

 

Download the presentation (PDF 2.0 MB)

Download the podcast (MP3 40 MB)

2014

Annual Results 2014 - Jan 27, 2015

 

    excl. Diagnostics[1] Reported
  FY 2014[2]
(USD m)		 FY 2013
(USD m)		 % change
(USD/cc[1])		 FY 2013
(USD m)
Net sales 57,996 57,355 1 (cc: 3) 57,920
Operating income 10,736 10,671 1 (cc: 7) 10,910
Net income 10,280 9,144 12 (cc: 19) 9,292
EPS (USD) 4.21 3.70 14 (cc: 20) 3.76
Free cash flow 10,762 9,592 12 9,945

Core1		        
Operating income 14,616 14,191 3 (cc: 8)  
Net income 12,755 12,351 3 (cc: 8)  
EPS (USD) 5.23 5.01 4 (cc: 10)  

 

 

1. Constant currencies (cc), core results, free cash flow and 2013 data excluding the blood transfusion diagnostics unit are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Financial Report (CFR).
2. 2014 results exclude depreciation and amortization related to discontinuing operations from the portfolio transformation announcement date. See page 22 of the CFR.

 

Media release

English (PDF 0.5 MB)

Deutsch (PDF 0.5 MB)

Français (PDF 0.8 MB)

Condensed financial report (PDF 0.6 MB)

2013

Annual Results 2013 - Jan 29, 2014

 

  FY 2013
(USD m)		 FY 2012[2]
(USD m)		 % change
(USD/cc[1])
Net sales 57,920 56,673 2 (cc: 4)
Operating income 10,910 11,193 -3 (cc: 5)
Net income 9,292 9,383 -1 (cc: 7)
EPS (USD) 3.76 3.83 -2 (cc: 6)
Free cash flow 9,945 11,383 -13

Core2		      
Operating income 14,485 14,842 -2 (cc: 3)
Net income 12,533 12,576 0 (cc: 5)
EPS (USD) 5.09 5.15 -1 (cc: 4)

 

 

1. Restated as explained in the the 2013 Condensed Financial Report on pages 36 and 72.
2. Constant currencies (cc), core results, and free cash flow are non-IFRS measures. An explanation of these non-IFRS measures and reconciliation tables can be found beginning on page 46 of the 2013 Condensed Financial Report.

See Annual Report 2013 for further information on core results

 

Media release

English (PDF 0.4 MB) Deutsch (PDF 0.4 MB) Français (PDF 0.6 MB)

 

Condensed financial report (PDF 0.4 MB)

2012

Annual Results 2012 - Jan 23, 2013


 

  FY 2012
(USD m)		 FY 2011
(USD m)		 % change
(USD/cc)
Net sales 56,673 58,566 -3 (cc: 0)
Operating income1 11,511 10,998 5 (cc: 8)
Net income 9,618 9,245 4 (cc: 7)
EPS (USD) 3.93 3.83 3 (cc: 6)
Free cash flow 11,383 12,503 -9

Core2		      
Operating income 15,160 15,909 -5 (cc: -2)
Net income 12,811 13,490 -5 (cc: -3)
EPS (USD) 5.25 5.57 -6 (cc: -3)

 

 

1. Q4 2012 operating income growth reflects the impact of higher exceptional charges in the 2011 period of USD 1.0 billion, principally due to USD 0.9 billion as a result of exceptional charges relating to Tekturna/Rasilez.
2. Core results, constant currencies, and free cash flow are non-IFRS measures. An explanation of these non-IFRS measures and reconciliation tables can be found beginning on page 45 of the condensed financial report.

See Annual Report 2012 for further information on core results

 

Media release

English (PDF 0.2 MB) Deutsch (PDF 0.2 MB) Français (PDF 0.2 MB)

 

Condensed financial report (PDF 0.4 MB)

Disclaimer: 

The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Related Links

Contact Investor Relations

Investors International:
Call +41 61 324 79 44

Investors North America:
Call +1 212 830 24 48

Novartis Share Registry:
For information relating to the registration of your shares, including name or address changes, please contact us by e‑mail or telephone:
Call +41 61 324 72 04